EMB vs XBI
iShares JP Morgan USD Emerging Markets Bond ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.39% for EMB.
- • EMB pays a higher dividend yield (5.37%).
Side-by-side metrics
| Metric | EMB | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.39% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.37% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $13.57B | $10.92B |
YTD return | 0.44% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.06 | 1.01 |
P/E ratio | — | — |
Last price | $92.06 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EMB top holdings
| XTSLA | BlackRock Cash Funds Treasury SL Agency | 0.50% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EMB
EMB (iShares JP Morgan USD Emerging Markets Bond ETF) is USD-denominated emerging market government bonds. Managed by iShares, the fund carries $13.6B in assets under management, an expense ratio of 0.39%, a dividend yield of 5.37%. Its largest holding is BlackRock Cash Funds Treasury SL Agency (XTSLA), which represents 0.5% of the portfolio.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.